(AOF) – OSE Immunotherapeutics announces that as of June 30, 2023, its available cash flow amounted to 15 million euros, ensuring financial visibility until the fourth quarter of 2024. In the first half of 2023, the biotech specialist in immuno -oncology and immuno-inflammation recorded a consolidated net loss of 11.84 million euros compared to a net loss of 1.97 million a year ago. Over this period, its turnover increased from 16 million to 1.35 million euros.
“OSE’s major priorities for 2023 and beyond will be to successfully lead Tedopi’s new pivotal phase 3 clinical program and maximize the short-term value of Lusvertikimab, while strengthening our business model based on on partnerships, ensuring recurring revenues through our ‘first-in-class’ programs”, announces Nicolas Poirier, Managing Director of OSE Immunotherapeutics.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
